Some active clinical trials targeting macrophages have HNSCC patient cohorts (e.g., NCT02216409, agent Hu5F9-G4 targeting CD47, and NCT02829723 agent BLZ945 targeting CSF1R). The gene discussed is CD47; the disease is head and neck squamous cell carcinoma.